A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1

• Egile Nagusiak: Dengqiu Xu (Egilea), Lei Zhao (Egilea), Jingwei Jiang (Egilea), Sijia Li (Egilea), Zeren Sun (Egilea), Xiaofei Huang (Egilea), Chunjie Li (Egilea), Tao Wang (Egilea), Lixin Sun (Egilea), Xihua Li (Egilea), Zhenzhou Jiang (Egilea), Luyong Zhang (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2020-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background Duchenne muscular dystrophy (DMD) is a progressive muscle disease caused by the loss of dystrophin, which results in inflammation, fibrosis, and the inhibition of myoblast differentiation in skeletal muscle. Catalpol, an iridoid glycoside, improves skeletal muscle function by enhancing my...